Drugs used in platelet disorders (Formulary)

ELTROMBOPAG

Important: Therapy notes

MHRA advice: Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results (July 2018) (www.gov.uk).

Important: Formulation and dosage details

Formulation:

Tablets 25mg, 50mg (hospital use only)

Dosage:

As per SMC 1206/17: chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (eg corticosteroids, immunoglobulins).
SMC restriction: use in patients with severe symptomatic ITP or a high risk of bleeding.

ROMIPLOSTIM

Important: Therapy notes


Risk minimisation materials

Important: Formulation and dosage details

Formulation:

Injection 250 micrograms (hospital use only)

ANAGRELIDE

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Capsules 500 micrograms (specialist initiation)

Editorial Information

Document Id: F291